» Articles » PMID: 24531764

Structure-based Programming of Lymph-node Targeting in Molecular Vaccines

Overview
Journal Nature
Specialty Science
Date 2014 Feb 18
PMID 24531764
Citations 410
Authors
Affiliations
Soon will be listed here.
Abstract

In cancer patients, visual identification of sentinel lymph nodes (LNs) is achieved by the injection of dyes that bind avidly to endogenous albumin, targeting these compounds to LNs, where they are efficiently filtered by resident phagocytes. Here we translate this 'albumin hitchhiking' approach to molecular vaccines, through the synthesis of amphiphiles (amph-vaccines) comprising an antigen or adjuvant cargo linked to a lipophilic albumin-binding tail by a solubility-promoting polar polymer chain. Administration of structurally optimized CpG-DNA/peptide amph-vaccines in mice resulted in marked increases in LN accumulation and decreased systemic dissemination relative to their parent compounds, leading to 30-fold increases in T-cell priming and enhanced anti-tumour efficacy while greatly reducing systemic toxicity. Amph-vaccines provide a simple, broadly applicable strategy to simultaneously increase the potency and safety of subunit vaccines.

Citing Articles

SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.

Cai Q, Guo R, Chen D, Deng Z, Gao J J Nanobiotechnology. 2025; 23(1):178.

PMID: 40050980 PMC: 11884119. DOI: 10.1186/s12951-025-03254-9.


AlbiCDN: albumin-binding amphiphilic STING agonists augment the immune activity for cancer immunotherapy.

Zhuo S, Chen X, Zhao L, Wang T, Su J, Yang T RSC Med Chem. 2025; .

PMID: 40008189 PMC: 11848399. DOI: 10.1039/d4md00475b.


Biomimetic Materials to Fabricate Artificial Cells.

Peng H, Zhao M, Liu X, Tong T, Zhang W, Gong C Chem Rev. 2024; 124(23):13178-13215.

PMID: 39591535 PMC: 11671219. DOI: 10.1021/acs.chemrev.4c00241.


Programmable Macrophage Vesicle Based Bionic Self-Adjuvanting Vaccine for Immunization against Monkeypox Virus.

Lin W, Shen C, Li M, Ma S, Liu C, Huang J Adv Sci (Weinh). 2024; 12(1):e2408608.

PMID: 39513669 PMC: 11714231. DOI: 10.1002/advs.202408608.


Advanced technologies for the development of infectious disease vaccines.

Gupta A, Rudra A, Reed K, Langer R, Anderson D Nat Rev Drug Discov. 2024; 23(12):914-938.

PMID: 39433939 DOI: 10.1038/s41573-024-01041-z.


References
1.
Barouch D, Pau M, Custers J, Koudstaal W, Kostense S, Havenga M . Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004; 172(10):6290-7. DOI: 10.4049/jimmunol.172.10.6290. View

2.
Salhab M, Patani N, Mokbel K . Sentinel lymph node micrometastasis in human breast cancer: an update. Surg Oncol. 2011; 20(4):e195-206. DOI: 10.1016/j.suronc.2011.06.006. View

3.
Tenbusch M, Ignatius R, Nchinda G, Trumpfheller C, Salazar A, Topfer K . Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques. PLoS One. 2012; 7(6):e39038. PMC: 3373620. DOI: 10.1371/journal.pone.0039038. View

4.
St John A, Chan C, Staats H, Leong K, Abraham S . Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater. 2012; 11(3):250-7. PMC: 3749235. DOI: 10.1038/nmat3222. View

5.
Liu H, Kwong B, Irvine D . Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy. Angew Chem Int Ed Engl. 2011; 50(31):7052-5. PMC: 3166645. DOI: 10.1002/anie.201101266. View